Documents & Downloads

KI-ARv-03

CDK9 Inhibitor

KI-ARv-03 is a potent and selective ATP-competitive inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC₅₀ of 0.15 μM in the presence of 45 μM ATP, with over 130-fold selectivity for CDK9 relative to other CDKs. This compound effectively reduces androgen receptor (AR)-driven transcription and cellular proliferation in prostate cancer models. KI-ARv-03 is applicable in the study of various malignancies, including leukemia, pancreatic cancer, alveolar rhabdomyosarcoma, and castration-resistant prostate cancer. Additionally, it serves as a ligand for PROTAC synthesis, specifically for generating PROTAC KI-CDK9d-32.

Out of Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer	Adooq Bioscience
Actions	Inhibitor
CAS Number	2416873-72-6
Applications	CDK9 Inhibitor
Formula	C₁₄H₂₁N₅
Molecular Weight	259.35
SMILES	CCCC1=NC2=CC=NN2C(N[C@H]3C[C@@H](CC3)N)=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.